At the news
? BULLISHIMPACT 6/10 PRESS-RELEASE filed Jul 20, 2026 at 16:00 ET
Gentherm received FDA 510(k) clearance for its ThermAffyx Patient Safety System, a Class II medical device combining active patient warming, securement, and pressure reduction for robotic-assisted surgeries. Revenue generation is expected to begin in Q3 2026, with product trials starting in August. This expands Gentherm's medical portfolio beyond automotive thermal management, but the near-term financial impact is modest relative to the company's ~$1.5B annual revenue base.
- FDA 510(k) clearance for ThermAffyx Patient Safety System, a Class II medical device
- Device combines active patient warming, securement, and pressure reduction for robotic-assisted surgeries
- Product trials begin August 2026; revenue expected to commence in Q3 2026
- Addresses a gap where only 17-21% of patient body surface area is available for forced-air warming in robotic procedures
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access